Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-Phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
View Patent ↗Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
1. A Form XXIII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuKa radiation: 4.1, 5.0, 6.3, 7.7, 8.5, 9.1, 10.5, 16.7, 18.4, 20.2, and 21.4.
2. A Form XXIII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuKa radiation: 3.2, 4.1, 5.0, 6.3, 7.2, 7.7, 8.1, 8.5, 9.1, 10.1, 10.5, 12.1, 12.8, 13.3, 16.7, 18.4, 19.1, 20.2, 21.0, 21.4, 23.2, 24.3, 25.2, and 29.3.
3. A Form XXIII atorvastatin calcium having an X-ray powder diffraction containing the following 2θ values measured using CuKa radiation: 4.1, 5.0, 6.3, 7.7, 8.5, 9.1, 10.5, 16.7, and 21.4.